​

Funding Round

Series D - Viamet Pharmaceuticals

Series D - Viamet Pharmaceuticals

Investment Firm

Overview

Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.

Announced Date

Oct 21, 2014

Funding Type

Series D

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

Hatteras Venture Partners

Hatteras Venture Partners

Hatteras Venture Partners is a convertible_note and early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorAstellas Venture Management
Participant InvestorLilly Ventures
Participant InvestorNovartis Venture Fund
Participant InvestorIntersouth Partners
Participant InvestorHatteras Venture Partners

Round Details and Background

Viamet Pharmaceuticals raised $60000000 on 2014-10-21 in Series D

Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.

Company Funding History

13

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 04, 2015
Grant - Viamet Pharmaceuticals
1-1.9M
Oct 21, 2014
Series D - Viamet Pharmaceuticals
5-60.0M
Jun 07, 2007
Series A - Viamet Pharmaceuticals
2-4.0M
Jul 07, 2009
Series B - Viamet Pharmaceuticals
6-25.0M

Recent Activity

There is no recent news or activity for this profile.